Rocket Pharmaceuticals, Inc. (RCKT) Financial Statements
Rocket Pharmaceuticals, Inc. (RCKT) reported trailing twelve-month revenue of $0 (up 915.6% year on year) and net income of -$17.3M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$170.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RCKTRocket Pharmaceuticals, Inc.Follow RCKT — free
—
Price chart with a free account
- Market cap
- 251.4M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Research & development | 12.6 | 6.0 | 14.9 | 53.3 | 57.9 | 105.4 | 125.5 | 165.6 | 186.3 | 171.2 | 142.0 | 124.4 | |
| Operating income | -20.4 | -7.6 | -19.8 | -71.2 | -76.2 | -134.3 | -167.2 | -224.3 | -259.7 | -273.2 | -231.7 | -191.6 | |
| Pre-tax income | -68.0 | -7.6 | -19.6 | -74.5 | -77.3 | -139.7 | -169.1 | -221.9 | -245.6 | -258.7 | -223.1 | -8.6 | |
| Income tax | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 8.6 | |
| Net income | -68.0 | -7.6 | -19.6 | -74.5 | -77.3 | -139.7 | -169.1 | -221.9 | -245.6 | -258.7 | -223.1 | -17.3 | |
| Diluted EPS ($) | -3.72 | -1.11 | -2.88 | -1.89 | -1.58 | -2.52 | -2.67 | -3.26 | -2.92 | -2.73 | -2.01 | -0.17 | |
| Diluted shares (mn) | — | — | — | — | — | — | 63.2 | 68.1 | 84.0 | 94.8 | 111.1 | — |
USD millions · SEC XBRL
Rocket Pharmaceuticals, Inc. — questions
- What is Rocket Pharmaceuticals, Inc.'s revenue?
- $0 over the twelve months to 2026-06-30, up 915.6% year on year, from its 10-Q and 10-K filings.
- What is Rocket Pharmaceuticals, Inc.'s net income?
- -$17.3M over the twelve months to 2026-06-30.
- What is Rocket Pharmaceuticals, Inc.'s free cash flow?
- -$170.4M over the twelve months to 2026-06-30.
- What are Rocket Pharmaceuticals, Inc.'s diluted earnings per share?
- $-0.17 over the twelve months to 2026-06-30.
Every figure on this page comes from Rocket Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.